GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CanSino Biologics 688185.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

75.33

+1.52%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.03bn

FY2016FY2025

Net income

CN¥27.2m

FY2016FY2025

Free cash flow

−CN¥152.8m

FY2016FY2025

Shareholders' equity

CN¥4.96bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.03bnCN¥725.5mCN¥295.9mCN¥1.03bnCN¥4.30bnCN¥21.3mCN¥2.0mCN¥970,426CN¥7.9mCN¥7.0m
Research and developmentCN¥230.5mCN¥356.7mCN¥546.9mCN¥778.3mCN¥878.7mCN¥367.3mCN¥130.1mCN¥97.4mCN¥58.4mCN¥44.3m
Operating income−CN¥113.1m−CN¥321.7m−CN¥1.74bn−CN¥1.37bnCN¥1.94bn−CN¥341.0m−CN¥173.2m−CN¥118.8m−CN¥54.7m−CN¥45.2m
Net incomeCN¥27.2m−CN¥324.8m−CN¥1.27bn−CN¥909.4mCN¥1.91bn−CN¥340.0m−CN¥131.3m−CN¥118.5m−CN¥55.3m−CN¥42.7m
Diluted earnings per share0.09-1.30-5.16-3.687.75-1.38-0.65-0.77-0.19-0.15

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥7.18bnCN¥7.96bnCN¥9.32bnCN¥11.47bnCN¥11.87bnCN¥5.78bnCN¥1.53bnCN¥682.3mCN¥742.7mCN¥279.6m
Cash and short-term investmentsCN¥2.65bnCN¥3.20bnCN¥4.12bnCN¥5.95bnCN¥7.78bnCN¥4.40bnCN¥647.1mCN¥169.2mCN¥360.8mCN¥125.6m
Total liabilitiesCN¥2.05bnCN¥3.05bnCN¥4.03bnCN¥4.22bnCN¥3.33bnCN¥580.6mCN¥269.2mCN¥251.7mCN¥222.1mCN¥95.8m
DebtCN¥1.29bnCN¥2.01bnCN¥2.70bnCN¥2.70bnCN¥1.37bnCN¥114.8mCN¥591.6mCN¥128.6mCN¥92.9mCN¥59.4m
Shareholders' equityCN¥4.96bnCN¥4.91bnCN¥5.27bnCN¥6.75bnCN¥8.00bnCN¥5.20bnCN¥1.26bnCN¥430.6mCN¥520.6mCN¥183.9m
Shares outstanding292m249m246m247m247m246m203m153m292m292m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥32.5m−CN¥144.7m−CN¥908.2m−CN¥1.89bnCN¥2.01bn−CN¥402.4m−CN¥145.9m−CN¥106.0m−CN¥48.3m−CN¥29.5m
Capital spending−CN¥185.3m−CN¥392.3m−CN¥610.5m−CN¥1.08bn−CN¥1.20bn−CN¥232.1m−CN¥100.3m−CN¥137.7m−CN¥159.4m−CN¥108.1m
Free cash flow−CN¥152.8m−CN¥537.0m−CN¥1.52bn−CN¥2.96bnCN¥811.4m−CN¥634.5m−CN¥246.2m−CN¥243.7m−CN¥207.6m−CN¥137.6m
Dividends paid—−CN¥54.7m−CN¥3.6m−CN¥193.9m−CN¥14.1m−CN¥5.7m−CN¥7.5m−CN¥6.5m−CN¥4.0m−CN¥288,303

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥358.0mCN¥188.6mCN¥369.8mCN¥310.1mCN¥245.2mCN¥137.2mCN¥239.4mCN¥263.6m
Operating incomeCN¥11.7m−CN¥41.8m−CN¥27.1mCN¥443,708−CN¥2.7m−CN¥16.5m−CN¥130.6mCN¥5.9m
Net incomeCN¥39.5m−CN¥40.1mCN¥13.2mCN¥27.9m−CN¥1.9m−CN¥11.5m−CN¥134.1mCN¥3.0m
Diluted earnings per share0.14-0.140.050.10-0.01-0.04-0.540.01
Cash from operations−CN¥5.0m−CN¥57.0mCN¥73.0mCN¥30.0mCN¥25.0m−CN¥13.0mCN¥102.0m−CN¥73.0m
Capital spending−CN¥26.0m−CN¥30.0m−CN¥64.0m−CN¥46.0m−CN¥67.0m−CN¥67.0m−CN¥112.0m−CN¥62.0m
Free cash flow−CN¥31.0m−CN¥87.0mCN¥9.0m−CN¥16.0m−CN¥42.0m−CN¥80.0m−CN¥10.0m−CN¥135.0m
Total assetsCN¥6.83bnCN¥6.97bnCN¥7.18bnCN¥7.30bnCN¥7.71bnCN¥7.82bnCN¥6.82bnCN¥7.99bn
Cash and short-term investmentsCN¥1.84bnCN¥2.07bnCN¥2.64bnCN¥2.47bnCN¥3.24bnCN¥3.09bnCN¥2.74bnCN¥3.28bn
DebtCN¥70.5mCN¥208.4mCN¥1.29bnCN¥365.0mCN¥1.89bnCN¥857.6mCN¥1.73bnCN¥1.13bn
Shareholders' equityCN¥4.98bnCN¥4.91bnCN¥4.96bnCN¥4.93bnCN¥4.90bnCN¥4.90bnCN¥4.34bnCN¥5.06bn

Financial ratios

Data as of 4 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin2.2%-44.3%-542.3%-114.1%45.1%-1598.3%
Net margin2.6%-44.8%-415.2%-87.9%44.5%-1593.6%
Return on equity0.6%-7.7%-28.1%-13.5%23.9%-6.5%
Return on assets0.4%-4.8%-15.9%-7.9%16.1%-5.9%
Free cash flow yield1.1%1.1%-1.2%-3.2%12.7%-0.8%
Revenue growth26.2%137.0%-65.5%-75.9%17174.8%59.4%
Earnings growth-107.4%-74.4%63.0%-147.5%-582.7%153.0%
Current ratio3.55x2.42x2.02x2.63x3.23x13.24x
Debt to equity0.19x0.41x0.48x0.37x0.14x0.02x
Equity ratio68.7%61.7%56.6%58.8%67.3%90.0%
Interest coverage0.60x-6.24x-30.19x-28.23x95.05x-15.01x
R&D as a share of sales29.3%49.2%178.7%75.2%20.4%1721.5%
Buybacks as a share of market value-17.0%-1.2%0.4%-0.1%-0.4%-20.9%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue0.0%117.2%—
Operating income-56.4%-19.8%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings—-46.8-14.4-39.738.6-270.6
Price to sales17.821.062.035.017.2—

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 23 Aug 2022.

FY2022
Paid in the year0.80

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.